Eikon Therapeutics Reports Q2 2026 Results and Clinical Updates

What Happened
Eikon Therapeutics, Inc. (EIKN) filed a Form 8-K on August 13, 2026 (Item 2.02) to report its results of operations and financial condition for the quarter ended June 30, 2026. The company issued a press release on that date with clinical and corporate updates and its quarterly financial results; the press release is furnished as Exhibit 99.1 to the 8-K. The filing is signed by Alfred Bowie, Ph.D., Chief Financial Officer.

Key Details

• Filing date: August 13, 2026; reporting period: quarter ended June 30, 2026.
• Item reported: 2.02 (Results of Operations and Financial Condition) — press release disclosing quarterly results and clinical/corporate updates.
• Exhibit 99.1: Press release dated August 13, 2026 is attached to the 8-K.
• Form was signed by Alfred Bowie, Ph.D., CFO; the filing also includes the Inline XBRL cover page (Exhibit 104).

Why It Matters
This 8-K signals that Eikon has released its latest quarterly results, and the accompanying press release will contain the details retail investors care about: earnings, revenue, cash position, pipeline/clinical progress, and any corporate developments. The 8-K itself does not add other disclosures beyond furnishing the press release, so investors should read the attached press release and the company’s full SEC filings for the specific financial figures and program updates before making decisions.